Pfizer and biontech's comirnaty® receives u.s. fda approval for adults 65 and older and individuals ages 5 through 64 at increased risk for severe covid-19

New york & mainz, germany--(business wire)--pfizer inc. (nyse: pfe, “pfizer”) and biontech se (nasdaq: bntx, “biontech”) today announced the u.s. food and drug administration (fda) has approved the supplemental biologics license application (sbla) for the companies' lp.8.1-adapted monovalent covid-19 vaccine (comirnaty® lp.8.1; covid-19 vaccine, mrna) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts the.
BNTX Ratings Summary
BNTX Quant Ranking